摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline | 288384-74-7

中文名称
——
中文别名
——
英文名称
4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline
英文别名
4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline
4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline化学式
CAS
288384-74-7
化学式
C23H26ClFN4O3
mdl
——
分子量
460.936
InChiKey
GRLLRVXZIWEVGT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    573.9±50.0 °C(Predicted)
  • 密度:
    1.272±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    32
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    60
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Quinazoline derivatives with anti-tumour activity
    申请人:AstraZeneca AB
    公开号:US20040048881A1
    公开(公告)日:2004-03-11
    The invention concerns quinazoline derivatives of Formula I 1 wherein each of m, R 1 , n, R 2 and R 3 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
    这项发明涉及式I的喹唑啉衍生物,其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义;它们的制备方法,含有它们的药物组合物以及它们在制造用作抗侵袭剂的药物的过程中在固体肿瘤疾病的控制和/或治疗中的使用。
  • [EN] QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE L'ANGIOGENESE
    申请人:ASTRAZENECA UK LTD
    公开号:WO2000047212A1
    公开(公告)日:2000-08-17
    The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C¿1-3?alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR?3R4¿ (wherein R?3 and R4¿, which may be the same or different, each represents hydrogen or C¿1-3?alkyl), or R?5X1¿- (wherein X?1 and R5¿ are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C¿1-4?alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R?56X10¿ (wherein X?10 and R56¿ are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    本发明涉及使用式(I)的化合物,其中环C是一个含有1-3个杂原子(独立选择自O、N和S)的8、9、10、12或13元的双环或三环基团;Z是-O-、-NH-、-S-、-CH2-或直接键;n为0-5;m为0-3;R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、-NR3R4(其中R3和R4,可能相同或不同,每个代表氢或C1-3烷基),或R5X1-(其中X1和R5如上定义);R1代表氢、氧代、卤代、羟基、C1-4烷氧基、C1-4烷基、C1-4烷氧甲基、C1-4烷酰基、C1-4卤代烷基、氰基、氨基、C2-5烯基、C2-5炔基、C1-3烷酰氧基、硝基、C1-4烷酰胺基、C1-4烷氧羰基、C1-4烷基硫基、C1-4烷基亚砜基、C1-4烷基磺酰基、氨基甲酰基、N-C1-4烷基氨基甲酰基、N,N-二(C1-4烷基)氨基甲酰基、氨基磺酰基、N-C1-4烷基氨基磺酰基、N,N-二(C1-4烷基)氨基磺酰基、N-(C1-4烷基磺酰基)氨基、N-(C1-4烷基磺酰基)-N-(C1-4烷基)氨基、N,N-二(C1-4烷基磺酰基)氨基、与两个环C碳原子连接的C3-7烷基链、C1-4烷酰胺基C1-4烷基、羧基或R56X10基团(其中X10和R56如上定义);以及其盐,在制备用于在温血动物中产生抗血管生成和/或血管通透性降低效应的药物中使用,制备这种化合物的过程,包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物和式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的效果,这是治疗包括癌症和类风湿性关节炎在内的许多疾病状态的有价值的属性。
  • [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
    申请人:ASTRAZENECA AB
    公开号:WO2002016352A1
    公开(公告)日:2002-02-28
    The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R?1, n, R2 and R3¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
    本发明涉及式(I)的喹唑啉衍生物,其中m、R1、n、R2和R3中的每一个具有在说明书中定义的任何含义;它们的制备过程,包含它们的制药组合物以及它们在制造用于抗侵袭剂治疗和/或治疗实体瘤疾病的药物中的使用。
  • Quinzoline derivatives for use in the treatment of cancer
    申请人:Hennequin Francois Andre Laurent
    公开号:US20050250797A1
    公开(公告)日:2005-11-10
    The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R 1 , n, R 3 ,Z 2 and R 14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
    本发明涉及公式(I)的喹唑啉衍生物,其中Z,m,R1,n,R3,Z2和R14中的每一个都具有本说明书中定义的任何含义;它们的制备过程,含有它们的制药组合物以及它们在制造用于抗侵袭或抗增殖剂的药物时,在包含和/或治疗实体肿瘤疾病方面的用途。
  • Quinazoline compounds with therapeutic use
    申请人:Moore Corine Nelly
    公开号:US20050009850A1
    公开(公告)日:2005-01-13
    The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of m, R 1 , Z, n and R 3 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
    本发明涉及在温血动物中预防或治疗T细胞介导的疾病或医疗状况的药物制剂的制造中使用式(I)的喹唑啉衍生物,其中m,R1,Z,n和R3中的每一个都具有描述中定义的任何含义。
查看更多